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Abstract
Nanoscale coordination polymers (NCPs) containing a Pt(IV) cisplatin prodrug,
disuccinatocisplatin, were formed by a surfactant-templated synthesis and were shown to have a
prodrug loading of 8.2 wt% and a diameter of ~133 nm by dynamic light scattering. These NCPs
were stabilized by coating with a DOPC/cholesterol/DSPE-Peg2K lipid layer; a release profile in
phosphate buffered saline showed an initial drug release of ~25% within the first hour and no
more release observed up to 192 h. The NCP was rendered target-specific for sigma receptors by
addition of an AA-DSPE-Peg2K conjugate (AA = anisamide) in the lipid formulation. The AA-
containing NCP showed a statistically significant decrease in IC50 (inhibitory concentration, 50%)
compared to the non-targeted NCP. Enhanced uptake of the AA-containing NCP was further
supported by confocal microscopy and competitive binding assays.
Introduction
Coordination polymers are hybrid materials formed by linking exo-multidentate ligands with
metal-connecting points and possess a number of beneficial properties including porosity,
high surface areas, and versatile functionalities. As a result, coordination polymers have
been explored for a number of applications such as catalysis,1–3 gas storage,4–7 nonlinear
optics,8 chemical sensing,9 and separations.10, 11 When scaled down to the nano-regime, the
resulting nanoscale coordination polymers (NCPs) can not only exhibit the same beneficial
properties as their bulk counterparts but also possess interesting functions that are unique to
nanomaterials. In particular, because of their synthetic tunability and intrinsic degradability,
NCPs have shown great promise in biomedical applications such as diagnostic imaging12–16
and drug delivery.17–20
Small molecule chemotherapeutics are used to treat many forms of cancer, but their efficacy
is compromised by a number of drawbacks, including poor pharmacokinetics, high systemic
toxicity, poor patient tolerance, and small therapeutic windows.21 Nanoparticulate
therapeutics can overcome many of these drawbacks and preferentially deposit in tumors by
taking advantage of the enhanced permeability and retention (EPR) effect22 and the ability
to actively target cancer cells. The EPR effect results from the ability of nanoparticles to
penetrate the leaky vasculatures of tumors and be retained due to poor lymphatic drainage.
Cisplatin, one of the three FDA-approved platin chemotherapeutics, is used to treat a variety
of cancers but has many side effects such as nephrotoxicity and neurotoxicity. We are
interested in designing novel strategies for targeted cisplatin delivery using NCPs. Although
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an earlier silica-coated NCP formulation was developed to deliver cisplatin at very high drug
loadings, this system suffers from the burst release of significant amounts of drug from the
particles.17 Other nanoscale platforms have been developed for cisplatin delivery but suffer
from low drug loadings, poor pharmacokinetics, and lower cytotoxicity than the free
drug.23–30 A PLGA-PEG-based nanoparticle system has been developed for delivery of a
cisplatin prodrug and has shown promising efficacy against prostate cancer cells.31, 32
Herein we report the synthesis and characterization of new cisplatin-containing NCPs which
have been stabilized by lipid coatings and functionalized with the targeting ligand,
anisamide (AA), a small molecule that displays an affinity for sigma receptors (Scheme 1).
The present NCP system shows enhanced efficacy compared to cisplatin in non-small cell
lung cancer (NSCLC) cell lines; increased uptake is further demonstrated by confocal
microscopy imaging and competitive binding assays.
Results and discussion
We first sought to synthesize a Zr-based NCP containing the Pt(IV) cisplatin prodrug,
disuccinatocisplatin (DSCP), in hope of taking advantage of the strong Zr-carboxylate
bond.33 Zr-DSCP NCPs (1a) were synthesized by acetone-induced precipitation of a
solution of ZrCl4 and DSCP in N,N-dimethylforamide (DMF). Particles of 1a are ~190 nm
in diameter by dynamic light scattering (DLS) and 100–200 nm by transmission electron
microscopy (TEM, Figure 1a). 1a has a high drug loading (27.1 wt%) by inductively-
coupled plasma mass sepctrometry (ICP-MS) analysis of Pt, but rapidly releases the
cisplatin cargo in phosphate buffered saline (PBS) with a half-life (t1/2) of ~30 min. Several
attempts to stabilize this material with surface coatings were unsuccessful (SI), presumably
due to the strong driving force of 1a to form Zr-phosphate particles in PBS.
In order to enhance the stability of cisplatin-containing NCPs under biologically relevant
conditions, we synthesized a La-DSCP NCP using La(III) ions as the metal-connecting
points. Lanthanide ions tend to have a better balance between particle stability and the
driving force to form phosphates.19 NCPs of La-DSCP (2a), capped with the lipid, 1,2-
dioleoyl-sn-glycero-3-phosphate (DOPA) were prepared by a surfactant-templated heating
technique. A water in cyclohexane reverse microemulsion of W = 7.4 (W = water:surfactant
molar ratio) containing TritonX-100, 1-hexanol, LaCl3, DSCP, and DOPA was heated in a
microwave at 70 °C for 10 min to afford 2a with a diameter of 50–150 nm by TEM (Figure
1b) and ~133 nm by DLS in tetrahydrofuran (THF), with a polydispersity index (PDI) of
0.12 (Figure 1c, Table 1). 2a has a DSCP loading of 8.2 wt% by ICP-MS.
Thermogravimetric analysis (TGA) indicates a high amount of organic weight loss for 2a,
indicating the presence of the DOPA coating (Figure S8, SI). 2a has a t1/2 of ~35 min in
phosphate buffered saline (PBS) at 37 °C.
Nanomaterials can be stabilized by lipid coatings.34 2a was coated with a lipid layer
composed of cholesterol (chol), 1,2- dioleoyl-sn-glycero-3-phosphocholine (DOPC), and
1,2- distearoyl-sn-glycero-3-phosphoethanolamine-N-(polyethylene glycol) (DSPE-Peg2K)
in a 2:2:1 molar ratio following a reported protocol.35 The size and morphology of lipid-
coated NCPs (2b) did not differ from those of 2a by TEM. 2b has a DLS diameter of ~163
nm in PBS, and is highly stable in PBS buffer, with ~25% Pt release within the first hour
and no additional release observed up to 192 h. The enhanced stability was supported by
time-dependent DLS measurements in the presence of bovine serum albumin in which the
particle size only decreases by ~20 nm and the PDI remains constant over 18 h (Figure S15,
SI).
2b was also modified with DSPE-Peg2K-AA (where AA is anisamide) to be rendered
cancer-specific. AA is a benzamide known to target sigma receptors, which are
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overexpressed on a number of epithelial tumor cells.36–38 AA-modified particles (2c) were
prepared by replacing DSPE-Peg2K with DSPE-Peg2K and DSPE-Peg2K-AA in a 9:1 molar
ratio during the lipid coating procedure for 2a. 2c has the same size and morphology as 2b
and displays similar stability characteristics as 2b by DLS. As cisplatin is the first-line
treatment for NSCLC, we subjected two NSCLC lines (NCI-H460 and A549) to in vitro
efficacy studies (Figure 2). NCI-H460 cells overexpress the sigma receptor and A549 have
lower expression, so studies on A549 cells were used as a negative control.
In vitro efficacies of 2a-c were determined over 48 h using the trypan blue exclusion assay.
In NCI-H460 cells, 2c showed superior efficacy to that of cisplatin with IC50 values of
cisplatin = 0.53 ± 0.14 μM, 2a = 5.57 ± 0.40 μM, 2b = 0.67 ± 0.06 μM, and 2c = 0.32 ± 0.03
μM. There is a statistically significant difference between the IC50 values for 2b and 2c by
the t test (α ≤ 0.05). Additionally, there was not a statistical difference in efficacy between
2b and 2c in A549 cells by the t test (α = 0.32), likely due to a low level of sigma receptor
expression in this cell line. Additionally, analysis by the t test also showed that there was not
a significant difference between IC50 values for cisplatin and 2b in either NCI-H460 (α =
0.21) or A549 (α = 0.12) cells.
Control vehicles, La NCP formulations that lack the cisplatin prodrug, were prepared from
succinic acid (Suc) using the same synthetic strategies for 2a. The La-Suc particles 3a were
lipid-coated (3b) and AA-targeted (3c) using the same method as 2a and display similar size
and morphology as the 2a-c. These NCPs were tested against NCI-H460 cells to show that
cytotoxicity of 2a-c originates from the cisplatin prodrug, not the La(III) metal or the lipid
coating. No cytotoxic effects were observed in the relevant particle concentration range
(Figure S21, SI).
Enhanced uptake of AA-targeted formulations was confirmed by laser scanning confocal
microscopy. Previously, we have shown that Ru(bpy)32+ is an efficient optical imaging
agent.15 Particles of 3c were doped with 10 mol% Ru(bpy)32+ by a surfactant-templated
synthesis, and were used for optical imaging by laser scanning confocal microscopy.
Particles of Ru(bpy)32+-doped 3a-c were incubated with NCI-H460 cells for 30 min and
imaged on a confocal microscope. Images show almost no fluorescence for 3a, as these
particles likely disintegrate before they are internalized. Slightly more fluorescence is
observed for 3b, but intense fluorescence is observed for 3c, indicating enhanced uptake due
to active targeting. Additionally, the mode of uptake was probed by confocal microscopy in
which NCI-H460 cells labeled with LysoTracker green were treated with Ru(bpy)32+-doped
3c. Co-localization of the green fluorescence from LysoTracker with red fluorescence from
3c indicates entrapment of the NCPs within lysosomes (Figure 4). In order to further verify
enhanced uptake of the targeted particles, competitive binding assays were conducted in
which the sigma receptors of NCI-H460 cells were saturated with NH3-Peg5K-AA, then
incubated with either 2b or 2c. As shown in Figure 3, the uptakes of both 2b or 2c are the
same when the cells have been saturated with an equal amount of NH3-Peg5K-AA, which
means that the active targeting ability of 2c is silenced. Additionally, even less 2c uptake is
observed when the cells are treated with a higher concentration of NH3-Peg5K-AA. When a
similar assay is done with A549 cells, no difference in NCP uptake between cells incubated
with 2b or 2c is observed after treatment with NH3-Peg5K-AA (Figure S22, SI).
Conclusions
We have developed a NCP formulation containing a cisplatin prodrug for targeted delivery
to non-small cell lung cancer cell lines. The NCP was stabilized with a cholesterol/DOPC/
DSPE-Peg lipid coating and made to actively target sigma receptors by doping with a
DSPE-Peg-anisamide conjugate. This formulation proved more potent than free cisplatin
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against NSCLC cell lines, and enhanced uptake was further demonstrated by confocal
microscopy and competitive binding assays. The generality of the present strategy should
allow the preparation of lipid-coated NCPs containing other chemotherapeutics for
efficacious treatment of cancers.
Experimental Section
Materials and General Procedures
All chemicals, unless otherwise noted, were purchased from Fisher Scientific or Sigma
Aldrich and used without further purification. Cisplatin (for synthesis of DSCP) was
purchased from AK Scientific. DOPA, DOPC), and DSPE-Peg2K were purchased from
Avanti Polar Lipids. Cell culturing supplies were purchased from Fisher Scientific.
LysoTracker green lysosomal marker was purchased from Life Technologies. Microwave
reactions were carried out in a CEM MARS 5 digestion microwave system. SEM images
were obtained on a Hitachi 4700 Field Emission Scanning Electron Microscope, and TEM
images were obtained on a JEM 100CX-II Transmission Electron Microscope. A
Cressington 108 Auto Sputter Coater equipped with a Au/Pd (80/20) target and MTM-10
thickness monitor was used to coat samples before SEM imaging. SEM micrographs were
obtained on glass slides, and TEM micrographs were obtained on carbon-coated copper
grids. TGA was performed on a Shimadzu TGA-50 equipped with a platinum pan, and
samples were heated at a rate of 3 °C/min under air. Size and zeta potential information was
obtained on a Malvern ZetaSizer dynamic light scattering instrument. Fluorescence spectra
were obtained on a Shimadzu RF-530PC spectrofluorophotometer. Confocal microscopic
images were obtained on glass slides and imaged on the Olympus FlowView confocal
microscope at the UNC-CH Microscope and Imaging Facility. Images were analyzed using
ImageJ (with the UCSD plugin) and PhotoShop.
Synthesis of Zr-DSCP NCP (1a)
NCPs of 1a were prepared by an acetone-induced precipitation technique. In a 150 mL
beaker, 34.8 mg (0.149 mmol) of ZrCl4 was dissolved in 13.5 mL of DMF, followed by the
addition of 80.4 mg (0.151 mmol) of DSCP and 270 μL of 3M (0.75 mmol, 5 eq.) acetic
acid. Stirring rapidly, ~100 mL acetone was poured into the DMF solution, resulting in a
white dispersion which was stirred at room temperature for 1 h, in the dark. The particles
were isolated by centrifugation and underwent subsequent wash/centrifugation steps once
with acetone and once with ethanol. The particles were dispersed in ethanol. Yield: 24 mg
(21.0 %).
Synthesis of La-DSCP@DOPA (2a)
Particles of 2a were prepared by a surfactant-assisted heating method. Two reverse (water in
oil) microemulsions were prepared in two 25 mL round bottom flasks by adding 5 mL 0.3 M
TritonX-100/1.5 M 1-hexanol in cyclohexane. To one flask was added (while stirring) 200
μL of aq. LaCl3·7H2O at a concentration of 25 mg/mL (5 mg, 0.0135 mmol, pH = 5.5), and
to the other flask was added 200 μL of aq. DSCP at a concentration of 25 mg/mL (5 mg,
0.01 mmol, pH = 4) and 30 μL of DOPA in CHCl3 at a concentration of 200 mg/mL (6 mg,
0.008 mmol). Both reverse microemulsions (W = 7.4) became clear instantly, were
combined in a microwave vessel, and microwaved at 70 ºC for 10 min using 400 W, 100%
power, and a 5 min ramping time. The white product was isolated by centrifugation,
subsequently washed/centrifuged once with THF, and dispersed in THF. Yield: 13.5 mg
(84.4 %).
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Synthesis of La-Suc@DOPA (3a) and Ru(bpy)32+-doped 3a
Particles of 3a were prepared by a similar surfactant-assisted heating method to 2a in 64.3%
yield. Particles of 3a doped with Ru(bpy)32+ were prepared by a similar surfactant-
templated method except that [Ru(5,5′-CO2H-bpy)(bpy)2](PF6)2 was added to the reverse
microemulsion.
Release Profiles
All release profiles were carried out in 5 mM PBS at 37 ºC. This concentration was chosen
because it exceeds the blood phosphate concentration. Between 2–4 mg NCPs were prepared
in 500 μL PBS or 30 % v/v EtOH/H2O and added to a length of 10K molecular weight
cutoff dialysis tubing. The dialysis tubing was submerged in a beaker containing 400 mL 5
mM PBS at 37 ºC. Aliquots of 1 mL each were removed from the beaker at designated time
intervals. Samples were digested in concentrated HNO3, diluted with H2O, and analyzed by
ICP-MS for Pt content. Pt content (in ppb) was converted to % drug released.
Cytotoxicity Assay of 2a-c against NCI-H460 or A549 Cells
Confluent NCI-H460 or A549 cells were trypsinized and a cell density was obtained from a
hemocytometer. Six-well plates were seeded with 5.0x104 cells/well and a total of 3 mL
media. Plates were incubated at 37°C and 5% CO2 overnight. Amounts of cisplatin or NCP
suspensions in RPMI-1640 medium were added to wells, along with additional media,
resulting in various cisplatin concentrations (μM). Plates were incubated at 37°C and 5%
CO2 for 48 h and viability was determined via the trypan blue exclusion assay.
Viability Assay of 3a-c against A549 Cells
Confluent A549 cells were trypsinized and a cell density was obtained from a
hemocytometer. Six-well plates were seeded with 5.0x104 cells/well and a total of 3 mL
media. Plates were incubated at 37°C and 5% CO2 overnight. Media was removed from
wells, and each well was washed with 2 mL PBS. Amounts of NCP suspensions in
RPMI-1640 medium were added to wells, along with additional media, resulting in various
amounts equivalent to μM cisplatin concentrations tested in the cytotoxicity assays. Plates
were incubated at 37°C and 5% CO2 for 24 h and viability was determined via the trypan
blue exclusion assay.
Confocal Microscopy Using NCI-H460 Cells
Confluent NCI-H460 cells were trypsinized and counted with a hemocytometer. Glass
coverslips were placed in the wells of six-well plates, followed by 2.0x105 cells/well and a
total of 3 mL media/well. Plates were incubated at 37 °C and 5 % CO2 overnight. Media
was removed from wells, and each well was washed with 2 mL PBS. Amounts of
Ru(bpy)32+-doped 3a-c (0.2 mg/well) were added with a total of 2 mL media/well. Wells
were incubated at 37 °C and 5 % CO2 for 30 min, media removed, wells washed with 1 mL
PBS, and coverslips adhered onto glass slides with antifade mounting medium. Images were
obtained on an Olympus FlowView500 confocal microscope.
Co-Localization Assay Using Confocal Microscopy
Confluent NCI-H460 cells were trypsinized and counted with a hemocytometer. Glass
coverslips were placed in the wells of six-well plates, followed by 2.0x105 cells/well and a
total of 3 mL media/well. Plates were incubated at 37 °C and 5 % CO2 overnight. A 100 nM
solution of LysoTracker green lysosomal marker was prepared in RMPI-1640 complete
growth medium. Media was removed from wells, and each well was washed with 2 mL
PBS. Each well received 3 mL dye solution and incubated for 2 h. Media was removed from
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wells, and each well was washed with 2 mL PBS. Ru(bpy)32+-doped 3c (0.2 mg/well) was
added with a total of 3 mL dye solution per well. Wells were incubated at 37 °C and 5 %
CO2 for 1 h, media removed, wells washed with 1 mL PBS, and coverslips adhered onto
glass slides with antifade mounting medium. Images were obtained on an Olympus
FlowView500 confocal microscope.
Competitive Binding Assay Using NCI-H460 or A549 Cells
Confluent NCI-H460 or A549 cells were trypsinized and counted with a hemocytometer.
Five T25 culture flasks were seeded with 1x106 cells/flask and 6 mL of complete growth
medium containing FBS. The flasks were incubated at 37 °C and 5 % CO2 for three days,
changing the media once during this time. Media was removed from the flasks, and each
flask was washed with 2 mL PBS. The flasks were given 3 mL media containing different
amounts of NH3-PEG5K-AA and incubated for 30 min. The media was removed, each flask
washed with 2 mL PBS, and 0.5 mg 2b or 2c were added to each flask with a total of 6 mL
media. The flasks were incubated for 30 min, trypsinized, and cell pellets were digested in
concentrated HNO3 for 2 days. Samples were diluted with H2O for a total of 4 mL 2%
HNO3 and analyzed by ICP-MS for La and Pt content.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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TEM images of (a) 1a and (b) 2a. (c) DLS plots of 2a, 2b, and 2c. (d) Release profiles of 2a
and 2b in PBS buffer at 37 °C.
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IC50 curves showing efficacy of free cisplatin and 2a–c against (a) NCI-H460 and (b) A549
cells. In vitro viability results showing no cytotoxic effects on (c) NCI-H460 and (d) A549
cells after treatment with 3a-c.
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Laser scanning confocal microscopy images showing DIC (b, d, f, h) and red fluorescence
(a, c, e, g) attributed to particle fluroescence: (a, b) control (no particles), (c, d) 2a, (e, f) 2b,
and (g, h) 2c. Scale bars = 20 μm. Competitive binding assays with NCI-H460 cells for (i)
La content and (j) Pt content.
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Laser scanning confocal microscopy images showing co-localization of Ru(bpy)32+-doped
3c (red fluorescence) with lysosomes labeled with LysoTracker green. (a) Red channel only,
(b) green channel only, (c) DIC, and (d) overlay of red and green channels. Scale bars = 20
μm.
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Schematic showing the lipid-coated and anisamide-targeted NCP formulations. Cisplatin
release from the NCP is presumably triggered by the acidic lysosomal pH followed by in
situ reduction of DSCP to cisplatin by endogenous thiol-based reductants such as gluathione.
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Table 2
IC50 Values for Cisplatin and DSCP NCPs.
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